Entrada Therapeutics (TRDA) EBIT Margin (2023 - 2025)
Historic EBIT Margin for Entrada Therapeutics (TRDA) over the last 3 years, with Q3 2025 value amounting to 2915.18%.
- Entrada Therapeutics' EBIT Margin fell 28045100.0% to 2915.18% in Q3 2025 from the same period last year, while for Sep 2025 it was 197.59%, marking a year-over-year decrease of 2244400.0%. This contributed to the annual value of 22.3% for FY2024, which is 247500.0% up from last year.
- Latest data reveals that Entrada Therapeutics reported EBIT Margin of 2915.18% as of Q3 2025, which was down 28045100.0% from 2402.51% recorded in Q2 2025.
- Entrada Therapeutics' EBIT Margin's 5-year high stood at 56.42% during Q2 2024, with a 5-year trough of 2915.18% in Q3 2025.
- Its 3-year average for EBIT Margin is 502.43%, with a median of 22.88% in 2023.
- As far as peak fluctuations go, Entrada Therapeutics' EBIT Margin surged by 1461200bps in 2024, and later plummeted by -28045100bps in 2025.
- Quarter analysis of 3 years shows Entrada Therapeutics' EBIT Margin stood at 11.72% in 2023, then crashed by -234bps to 15.69% in 2024, then tumbled by -18482bps to 2915.18% in 2025.
- Its EBIT Margin was 2915.18% in Q3 2025, compared to 2402.51% in Q2 2025 and 105.99% in Q1 2025.